Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter study to evaluate the systemic exposure and safety of
topical tapinarof cream, 1% under conditions of maximal use in pediatric subjects with atopic
dermatitis